Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1531-1540

  Vichaya, Elisabeth G ^a   Wang, Xin Shelley ^a   Boyette Davis, Jessica A ^b   Mendoza, Tito R ^a   He, Zijing ^a   Thomas, Sheeba K ^a   Shah, Nina ^a   Williams, Loretta A ^a   Cleeland, Charles S ^a   Dougherty, Patrick M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b York College   (United States)

Author keywords

Bortezomib; Multiple myeloma; Patient reported outcome; Peripheral neuropathy; Quantitative sensory testing

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VORINOSTAT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; COLD SENSATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HEAT SENSATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PARESTHESIA; PERCEPTIVE THRESHOLD; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SENSORY DYSFUNCTION; SENSORY EVALUATION; SKIN TEMPERATURE; TOUCH; WALKING DIFFICULTY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYPESTHESIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; SENSORY THRESHOLDS;

EID: 84878644815     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2152-7     Document Type: Article

References (45)

1. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8(8):2505-2511
2. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129(6):776-783. doi: 10.1111/j.1365-2141.2005. 05540.x
3. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29(11):1472-1478. doi: 10.1200/JCO.2010.33.0308
4. Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22-E28. doi: 10.1188/10.CJON.E22-E28
5. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13(4):275-282. doi: 10.1111/j.1529-8027.2008.00193.x
6. Prince HM, Adena M, Smith DK, Hertel J (2007) Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. Eur J Haematol 79(2):93-99. doi: 10.1111/j.1600-0609.2007.00886.x
7. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113-3120. doi: 10.1200/JCO.2005.04.7779
8. Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM (2011) Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain 12(9):1017-1024. doi: 10.1016/j.jpain.2011.04.008
9. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M, De Coster R (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204(1):317-325. doi: 10.1016/j.expneurol.2006.11.010
10. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G (2002) Thalidomide-induced neuropathy. Neurology 59(12):1872-1875
11. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906-917. doi: 10.1056/NEJMoa0801479
12. Cavaletti G, Jakubowiak AJ (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 51(7):1178-1187. doi: 10.3109/10428194.2010.483303
13. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Yakoub Agha I, Bourhis JH, Garderet L, Pegourie B, Dumontet C, Renaud M, Voillat L, Berthou C, Marit G, Monconduit M, Caillot D, Grobois B, Avet-Loiseau H, Moreau P, Facon T (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289-3294. doi: 10.1182/blood-2006-05-022962
14. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, Garcia-Larana J, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, Gonzalez Y, Hernandez JM, Sureda A, Bello JL, Bargay J, Penalver FJ, Ribera JM, Martin-Mateos ML, Garcia-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalban MA, Lahuerta JJ, Blade J, Miguel JF (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11(10):934-941. doi: 10.1016/S1470-2045(10) 70187-X
15. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M (2010) Bortezomib-melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28(34):5101-5109. doi: 10.1200/JCO.2010.29.8216
16. Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, Mulligan G, Harousseau JL, Richardson PG, Ricci DS (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21(3):121-129. doi: 10.1097/FPC.0b013e3283436b45
17. Johnson DC, Ramos C, Szubert AJ, Gregory WM, Child JA, Davies FE, Durie BG, Van Ness BG, Morgan GJ (2008) Genetic variation in ADME genes is associated with thalidomide related peripheral neuropathy in multiple myeloma patients. ASH Annu Meet Abstr 112(11):1675
18. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110(5):1042-1049. doi: 10.1002/cncr.22921
19. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Diaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108(7):2165-2172. doi: 10.1182/blood-2006-04-019778
20. Bruna J, Ale A, Velasco R, Jaramillo J, Navarro X, Udina E (2011) Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J Peripher Nerv Syst 16(3):199-212. doi: 10.1111/j.1529-8027.2011.00346.x
21. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D, La Presa MT, Lissoni A, Buda A, Fei F, Cundari S, Zanna C (2004) Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 15(9):1439-1442. doi: 10.1093/annonc/mdh348
22. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86(1):23-31. doi: 10.1111/j.1600-0609.2010.01533.x
23. Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petro D, Jann S, Cavaletti G (2008) Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 13(4):267-274. doi: 10.1111/j.1529-8027.2008.00192.x
24. He Z, Boyette-Davis JA, Shah ND, Thomas SK, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM (In Preparation) Subclinical peripheral neuropathy is a common finding in multiple myeloma patients prior to chemotherapy
25. Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM (2012) Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18(11):3180-3187. doi: 10.1158/1078-0432.CCR-12- 0205
26. Felix ER, Widerstrom-Noga EG (2009) Reliability and validity of quantitative sensory testing in persons with spinal cord injury and neuropathic pain. J Rehabil Res Dev 46(1):69-83
27. Geber C, Klein T, Azad S, Birklein F, Gierthmuhlen J, Huge V, Lauchart M, Nitzsche D, Stengel M, Valet M, Baron R, Maier C, Tolle T, Treede RD (2011) Test-retest and interobserver reliability of quantitative sensory testing according to the protocol of the German Research Network on Neuropathic Pain (DFNS): a multi-centre study. Pain 152(3):548-556. doi: 10.1016/j.pain.2010.11. 013
28. Krumova EK, Geber C, Westermann A, Maier C (2012) Neuropathic pain: is quantitative sensory testing helpful? Curr Diab Rep 12(4):393-402. doi: 10.1007/s11892-012-0282-7
29. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM (2007) Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8(4):296-306. doi: 10.1016/j.jpain.2006.09.014
30. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR (2007) Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manag 33(2):166-179. doi: 10.1016/j.jpainsymman.2006.08.006
31. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1-2):132-142. doi: 10.1016/j.pain.2004.01.021
32. Fuchs PN, Campbell JN, Meyer RA (2000) Secondary hyperalgesia persists in capsaicin desensitized skin. Pain 84(2-3):141-149
33. Ruff RM, Parker SB (1993) Gender- and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the finger tapping and grooved pegboard tests. Percept Mot Skills 76(3 Pt 2):1219-1230
34. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634-1646. doi: 10.1002/1097-0142(20001001)89: 7<1634:AID-CNCR29>3.0.CO;2-V
35. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR (2013) Validation of the M. D. Anderson symptom inventory multiple myeloma module. J Hematol Oncol 6(1):13. doi: 10.1186/1756-8722-6-13
36. Palos GR, Mendoza TR, Mobley GM, Cantor SB, Cleeland CS (2006) Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain 7(1):49-56. doi: 10.1016/j.jpain.2005.07.012
37. Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18(4):673-688. doi: 10.1016/j.beha.2005.01.024
38. Drappatz J, Batchelor T (2004) Neurologic complications of plasma cell disorders. Clin Lymphoma 5(3):163-171
39. Treede RD, Meyer RA, Raja SN, Campbell JN (1995) Evidence for two different heat transduction mechanisms in nociceptive primary afferents innervating monkey skin. J Physiol 483(Pt 3):747-758
40. Cain DM, Khasabov SG, Simone DA (2001) Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: an in vivo study. J Neurophysiol 85(4):1561-1574
41. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116(23):4745-4753. doi: 10.1182/blood-2010-07-294983
42. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165-172. doi: 10.1111/j.1365-2141.2004.05188.x
43. Offidani M, Corvatta L, Marconi M, Malerba L, Mele A, Olivieri A, Brunori M, Catarini M, Candela M, Capelli D, Montanari M, Rupoli S, Leoni P (2004) Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 72(6):403-409. doi: 10.1111/j.1600-0609.2004.00238.x
44. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050-4053. doi: 10.1182/blood-2005-07-2817
45. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine D-L, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau J-L (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431-440